AMGN241227P290000
- 22.60
- 0.000.00%
Amgen Newsroom
Looking At Amgen's Recent Unusual Options Activity
Medical stocks welcome a rebound opportunity: three major star companies may become investment highlights in 2025.
In 2024, the performance of the Medical Industry is disappointing for investors, but 2025 may bring a glimmer of hope.
3 Healthcare Stocks to Buy for a 2025 Rebound
Top Dividend Picks for 2025 According to Seeking Alpha's Quant Metrics
10 Health Care Stocks With Whale Alerts In Today's Session
Weight-loss Drugs in 2025, Auto Industry Outlook: Market Domination
Is Amgen (NASDAQ:AMGN) a High-Quality Dividend Stock on Sale?
Why the 'Dogs of the Dow' Stocks Just Might Deliver in 2025
Sector Update: Health Care Stocks Advance Late Afternoon
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
Spotlight on Amgen: Analyzing the Surge in Options Activity
Lilly, Amgen Sue HHS Over Certification of Drug Discount Program Recipients
Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
What's Going On With Amgen Stock On Friday?
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Cuts Target Price to $350
Goldman Sachs, Salesforce Share Gains Lead Dow's 300-Point Jump
Why Is Novo Nordisk Crashing After Data for Next-gen Weight Loss Drug?
U.S. stock market fluctuations | Amgen once rose over 3%, competing company Novo-Nordisk A/S's weight loss drug trial results fell short of expectations.
On December 20, the stock of Amgen (AMGN.US) rose more than 3% to $269.61 at the beginning of trading. According to reports, Novo-Nordisk A/S announced the main results of a Phase 3 clinical trial named REDEFINE 1 on Friday. When assessing the treatment effect for all patients who adhered to the treatment, those treated with CagriSema experienced a weight loss of 22.7% after 68 weeks, which was lower than the market expectation of 25%. The stock price of Novo-Nordisk A/S plummeted over 20%. (Gelonghui)
Express News | Shares of Viking Therapeutics up 4.2%, Amgen up 1%